Slideshow

Refined Prediction of MACE in Subclinical Atherosclerosis

Author(s):

Veronica Hackenthal, MD

New study finds that noninvasive assessment of CAD with CCTA may help reclassify risk and predict MACE in asymptomatic atherosclerosis.

Source: Guaricci AI, Lorenzoni V, Guglielmo M, et al. Prognostic relevance of subclinical coronary and carotid atherosclerosis in a diabetic and nondiabetic asymptomatic population. Clin Cardiol. 2018;41:769-777.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM | Image Credit: Radcliffe Cardiology
Related Content
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
November 23rd 2024

FDA Approves Acoramidis (Attruby) for ATTR-CM

Patrick Campbell
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Steve Nissen, MD | Credit: Cleveland Clinic
November 18th 2024

Zerlasiran 60-Week Data Reinforce Lp(a) Reductions Observed in ALPACAR-360

Patrick Campbell
Kidney Compass default thumbnail with podcast logo and headshots of hosts Brendon Neuen and Shikha Wadhwani.
October 28th 2024

Kidney Compass: FLOW Insights from Kidney Week 2024, with Katherine Tuttle, MD

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
Bumetanide Nasal Spray Equivalent to Oral, IV Forms for Heart Failure| Image Credit: American Heart Association
November 18th 2024

Bumetanide Nasal Spray Equivalent to Oral, IV Forms for Heart Failure

Connor Iapoce
Sacubtril/Valsartan Lowers Risk of Cardiotoxicity Linked to Chemotherapy | Image Credit: American Heart Association
November 18th 2024

Sacubtril/Valsartan Lowers Cardiotoxicity Risk Linked to Chemotherapy

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.